Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US
Mylan Partnership Bears Fruit
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.
You may also be interested in...
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Strides has paused further investments in the sterile injectables business under Stelis, citing pandemic-related uncertainty and loss of revenue from ranitidine withdrawal in the US. A prior investment commitment of $40m in Stelis will, however, be fulfilled. Meanwhile, Strides reported a strong first quarter led by non-US markets.